Serum gp91phox/NOX2 Level Among Patients with Subclinical Hypothyroidism, and Its Relation to Atherogenic Indices

Background and objectives: Subclinical hypothyroidism is emphasized by a normal serum-free thyroxin4 concentration as well as an elevated thyroid stimulating hormone concentration, Gp91phox, the catalytic key of nicotinamide-adenine-dinucleotide-phosphate-oxidase and predictor of its activation, has lately been examined as an indicator of systemic oxidative. The current study aimed to assess the level of serum gp91phox among patients with subclinical hypothyroidism. Methods: The current case-control study included 160 participants: 80 newly diagnosed subclinical hypothyroidism patients were obtained from the Diabetic and Endocrinology Unit at Azadi Teaching Hospital, and 80 healthy individuals, lasted eight months from November 2022 to July 2023. Lipid profile and thyroid function tests have been done for. The serum soluble gp91phox level was compared between both groups. Results: The mean serum gp91phox was higher among subclinical hypothyroidism cases (9.06 ± 4.80 ng/mL) than among healthy individuals (7.40 ±3.42 ng/mL). There was a statistically significant elevation of the mean of atherogenic-index of plasma in cases (0.39, p. value = 0.049) compared to the controls (0.30, p. value = 0.049), and the mean of Castelli Risk Index II in cases (2.18, p. value = 0.008) was significantly greater than that of the controls (1.86, p. value = 0.008) in subclinical hypothyroidism. Conclusion: There was a significantly higher mean serum level of gp91phox/NOX2 in patients with subclinical hypothyroidism.